PMB will be joining the LSX USA Congress in Boston, September 16–17! We look forward to collaboration on biotech advancements such as Immune¹², our groundbreaking marine-sourced complex biologic targeting Glioblastoma (GBM), one of the most aggressive forms of brain cancer. If you’re active in oncology, biologics, or exploring investment opportunities in next-gen therapeutics, we would love to connect. Let’s talk science, strategy, and the future of neuro-oncology.